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A B S T R A C T
Multidrug resistance (MDR) is one of the serious problems in cancer research that causes failure in
chemotherapy. Chromene-based compounds have been proven to be the novel anti-MDR agents for
inhibiting proliferation of tumor cells through tubulin polymerization inhibition of by binding at the
colchicine binding site. In this study, we screened a chromene-based database of small molecules using
physicochemical, ADMET properties and molecular docking to identify potential hit compounds. In order
to validate our hit compounds, molecular dynamics simulations and related analysis were carried out and
the results suggest that our hit compounds (PubChem CIDs: 16814409, 17594471, 57367244 and
69899719) can prove to be potential inhibitors of tubulin. The in silico results show that the present hits,
like colchicine, effectively suppressed the dynamic instability of microtubules and induced microtubule-
depolymerization and cell cycle arrest.
© 2017 Elsevier Ltd. All rights reserved.
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Cancer is the result of uncontrolled cell proliferation, where
transformed normal cells (malignant cells) aggressively divide and
spread to other areas of human body through metastasis. During
the last decades, no signiﬁcant improvements have been made in
the ﬁeld of approved conventional therapeutic drugs due to their
side effects. Limited clinical effectiveness, probable resistance and
toxicity remain serious problems, associated with the existent
anticancer drugs (Temraz et al., 2014). The World Health
Organization (WHO) had estimated 14.1 million cancer cases
and up to 8.2 million cancer-related mortality cases in 2012 (Bray
et al., 2013).
The emergence of drug-resistant tumor cells is rapidly
becoming a major worldwide problem. Therefore, ﬁnding new
drugs to overcome this resistance has become one of the most
important goals of recent medical researches. In general, the
cancer cells exhibit unusual inhibition of apoptosis, hence many
commonly used chemotherapeutic drugs induce tumor cell* Corresponding author.
E-mail address: h.aryapour@gu.ac.ir (H. Aryapour).
https://doi.org/10.1016/j.compbiolchem.2017.09.007
1476-9271/© 2017 Elsevier Ltd. All rights reserved.apoptosis (Waxman and Schwartz, 2003; Patil et al., 2013). The
pro-apoptotic chemotherapeutic agents that interfere directly
with the tubulin system, are the most successful and commonly
prescribed anticancer therapeutics. The importance of tubulin
protein in mitosis and cell division, makes it an important target of
anticancer drugs. These drugs can react or bind at various sites on
tubulin; such as their sulfhydryl (-SH) groups. It is evident that
many new anticancer chemotherapeutic drugs function by
targeting a/b-tubulin. The colchicine binding site is one of the
most important pockets for potential tubulin inhibitors for the
development of apoptotic-inducing chemotherapeutic agents.
Over the last few years, our Organic Chemistry group has been
focused on the development of new eco-friendly methods for the
synthesis of bioactive heterocyclic compounds, including the
preparation of chalcones, ﬂavonols, and chromene derivatives
(Saffari et al., 2014; Aryapour et al., 2012a,b, 2011).
The chromenes inhibit tubulin polymerization and bind at or
close to the colchicine binding site. Chromene scaffold is an
important class of benzopyran derivatives found in plants,
including edible vegetables and fruits (Curini et al., 2006).
Chromenes and their derivatives play a pivotal role in the scope
of natural and synthetic organic chemistry because of their
Fig. 1. Plot of polar surface area (PSA) against solubility (LogS) after the ﬁltration of
compounds, based on physicochemical properties. The area encompassed by the
ellipse is a prediction of good absorption by blood-brain barrier (Cyan color) and
Caco-2 Permeability (Pink color) with no violation of ADMET properties.(For
interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
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the form of anti-HIV (Smith et al., 1998; Mungra et al., 2011),
anticancer, anticoagulant, diuretic, spasmolytic, anti-anaphylactic
(Foye and Piccin, 1991), antibacterial and fungal agents (Khafagy
et al., 2002). Chromene-based compounds have been proven to be
one of the novel anti-MDR agents that inhibit proliferation of
tumor cells through the inhibition of tubulin polymerization by
binding at the colchicine binding site (Patil et al., 2013).
Two main approaches are currently available for drug discovery
research, namely, high throughput screening (HTS) and computer-
aided drug design. Despite the development in HTS approach, the
screening of all compounds, using biological assays is still very
expensive, difﬁcult and time-consuming. In the last two decades,
advances in computational programming and processing power
have made the structure-based virtual screening (SBVS) an
important tool to identify starting points for the discovery of
new potentially active molecules that can be called “Hit”
compounds (Tanrikulu et al., 2013; Muegge, 2008; Walters et al.,
1998; M.I.O.S, 2006).
In this study, we employed a set of in silico methods such as
docking procedure, virtual screening techniques and molecular
dynamics (MD) simulation as well as the analysis of Absorption,
Distribution, Metabolism, and Excretion (ADME), for ﬁltering a
large set of chromene compounds in order to ﬁnd new scaffolds for
colchicine-binding site of tubulin. Molecular dynamics simulation
techniques were used to predict more reliable protein-ligand
complex structures. The results described here, can provide a
valuable dataset of chromene inhibitors for future experimental
studies.
2. Materials and methods
2.1. Protein preparation
The X-ray structure of a/b-tubulin (PDB ID: 4O2B, resolution:
2.30 Å (Prota et al., 2014)) was obtained from Protein Data Bank
(Berman et al., 2000). First, additional parts of PDB ﬁle, except for
chains d, c and related heteromolecules were removed. Missing
residues and parts of tubulin were added and reﬁned using UCSF
Chimera graphical interface in MODELLER software (Fiser et al.,
2000). Then, ﬁnal complex was simulated by GROMACS to reach
the equilibrium state
2.2. Ligand selection and preparation for docking
Structure-based virtual screening was employed to screen two
chemical databases: ZINC (Irwin and Shoichet, 2005) and
PubChem (Kim et al., 2016) to discover novel inhibitors of 4O2B.
Totally, 117 thousand chromene-based structures were down-
loaded from ZINC and PubChem databases. Because of the
existence of non-chromene compounds in downloaded ﬁle, all
chromene-based isomers were extracted from these ﬁles and the
duplicates were excluded.
2.3. Filtering and virtual screening
Virtual screening of known chemical databases is a fast and
accurate method, which serves the purpose of identifying potential
hits, suitable for further developments. Before the virtual
screening by docking, compounds that were expected to be
unsuitable drugs or those having toxic and poor ADME properties,
were ﬁrstly eliminated by using a series of simple pharmaco-
dynamic or pharmaco-kinetic descriptors; such as Lipinski’s Rule
of Five (RO5) (Lipinski et al., 2001). Most of the drugs failed indevelopmental stages of clinical trials, due to their poor
pharmacokinetic parameters. RO5states that a molecule is likely
to be orally active if it satisﬁes the following conditions: (a) the
molecular weight should be below 500, (b) the calculated octanol/
water partition coefﬁcient (log P) should be less than 5, (c) number
of hydrogen bond donors (e.g.;OH and NH groups) should not
exceed 5, and (d) number of hydrogen bond acceptors (notably N
and O) should not exceed 10. There are exceptions to this rule as
well: a compound is likely to be orally active as long as not more
than one rule is broken. Extensions of RO5 state that polar surface
area should likely be less than or equal to 140 Å2 and the number of
rotatable bonds should be less than or equal to 10 (Veber et al.,
2002). Molecular polar surface area (PSA) is an important property
in calculating the transport properties of drugs. Surface areas of
polar atoms in a molecule, usually oxygen, nitrogen and attached
hydrogens are summed up to calculate the polar surface area as a
sum of fragment contributions as per the previously reported
method (Ertl et al., 2000). In the present study, the RO5, ADME and
toxicological (collectively ADMET) properties for compounds were
performed using DruLiTo software, and CypRules and admetSAR
servers (Cheng et al., 2012; Shao et al., 2015). Compounds that
passed the RO5 were further assessed for the prediction of ADMET
properties. ADMET descriptors, including aqueous solubility,
blood-brain barrier (BBB) penetration, cytochrome P450, hepato-
toxicity, human intestinal absorption (HIA), and plasma-protein
binding (PPB) were estimated for RO5 testiﬁed. Finally, the total
number of compounds reached 2204 after ﬁltering. The ﬁnal
structures were prepared for molecular docking by merging non-
polar hydrogens, assigning gasteiger charges on each atom.
AutoDock Vina software, which is one of the most accurate
docking techniques, was used for docking computations (Trott and
Olson, 2010).
2.4. Molecular docking setup
Docking process is one of the most widespread virtual
screening approaches in computational drug discovery research.
The docking technique consists of sampling the ligand orientations
within targets’ binding site to form a stable complex. The hit
compounds, obtained from the virtual screening analysis, were
used in the docking calculation to investigate the detailed
intermolecular interactions between a ligand and its receptor.
The molecular docking studies were carried out to explore the
interaction mechanisms between virtual hits and the receptor.
Table 1
Results of molecular docking scores and X-score of top 4 hit compounds inside the
binding site of colchicine.
Hits Binding afﬁnity (Kcal mol1) X-score
17594471 10.7 6.78
69899719 10.3 6.36
16814409 9.6 6.24
57367244 10.2 6
Colchicine 9.3 5.25
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positive results of molecular docking. This was done by the
calculation of Root Mean Square Deviation (RMSD) value with
respect to the co-crystallized ligands. If the RMSD value is equal to
or less than 2.0 Å between the real and the best-scored
conformations he docking process will be considered successful
(Wang et al., 2003). In order to validate the docking procedure,
native ligand of the crystal structure was removed from binding
site and was re-docked into the binding site of 4O2B. The RMSD
between the predicted and observed conformations of native
ligand of crystal structure (PDB ID: 4O2B) is equal to 0.6 Å. This
value that suggests that the reliability of the AutoDock Vina
docking mode in reproducing the experimentally observed binding
mode for 4O2B inhibitors and the parameter, set for docking, is
reasonable to reproduce the X-ray structure. On the basis of this
method, we can conclude that the docking method was validated
and reliable for further calculations.
Default parameters in AutoDock Vina that were followed for the
docking studies of virtual hits included the processing of protein
and ligand. All the virtual hits were docked into the active site of
tubulin, (4O2B) using AutoDock Vina program. During protein
preparation, ligand and solvent molecules were deleted, and the
hydrogen atoms were added to it. Each protein structure and ligand
was converted from a PDB ﬁle type to pdbqt format and a grid box
with the speciﬁed coordinates (X = 115.373, Y = 90.489 and
Z = 46.358) was generated at the centroid of the active site.Fig. 2. Chemical structure of the top 4 hit compounds and their IUPAC name. 16814
carboxamide; 69899719, 4-[6-[(2,4-diaminopyrimidin-5-yl)methyl]-8-methoxyspiro[c
pyridin-2-ylpiperazin-1-yl)ethoxy]spiro[3H-chromene-2,40-piperidine]-4-one; 5736724For each docked ligand, scoring function values were obtained
at ten different binding conﬁrmations. Each pose suggests the best
binding conformation, energy and binding site of the drug into
tubulin (4O2B) in a cycle of runs. Finally, the lowest binding energy
pose was selected among 10 docking poses for downstream
analysis. Following in silico molecular docking, the receptor-ligand
complexes were analyzed using PoseView server (Stierand and
Rarey, 2007) to delineate the amino acid residues, which are
involved in receptor-ligand interaction.
For comparison and validation of docking results, we used a
consensus scoring function of X-Score (Wang et al., 2002). This
program has three built-in scoring functions, HPScore, HMScore,
HSScore and calculates the negative logarithm for the dissociation
constant of the ligand-protein as the average of three scoring
functions, and predicts the binding afﬁnity (Kcal/mol) of the
ligand. All the default parameters of X-Score program were used
during this analysis.
2.5. Molecular dynamics simulation
MD simulations are useful for ﬁlling-in the details where
experimental methods cannot (Durrant and McCammon, 2011).
MD techniques have been applied to predict more reliable protein-
ligand complexes. MD simulations can treat both ligand and
protein in a ﬂexible way, allowing for an induced ﬁt of the receptor-
binding site around the newly introduced ligand. In addition, the
effect of explicit water molecules can be studied directly, and very
accurate binding free energies can be obtained via this method. In
the present study, in order to further validate the rationality of the
molecular docking results and the structural stability of the 4O2B–
hits complexes, MD simulation was performed with GROMACS
5.0.5 software package (Van Der Spoel et al., 2005). The topology
ﬁles of the 4O2B were directly generated by GROMACS, whereas
SwissParam server was used to generate topology ﬁles of the hit
compounds (Zoete et al., 2011).
The general charmm27 force ﬁeld (Brooks et al., 2009) was used
for the hits and the protein. For the MD simulation studies, all of
the complexes were immersed in the center of a triclinic box with a409, N-[2-[(3-methoxyphenyl)carbamoyl]-1-benzofuran-3-yl]-2-oxochromene-3-
hromene-2,10-cyclobutane]-4-yl]benzonitrile; 17594471, 10-acetyl-7-[2-oxo-2-(4-
4, 4-[benzyl(3-phenylprop-2-enyl)amino]-2-oxochromene-3-carbaldehyde.
Fig. 3. The RMSD of 4O2B complexes during 10 ns MD simulations.
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water model. The box dimensions were 87.389 Å  114.695 Å
 126.027 Å with 303 SPC water molecules. Enough sodium and
chloride ions were added to neutralize the charges in the systems.
Each complex was ﬁrstly energy-minimized, using steepest
descent minimization algorithm, until the maximum force was
found to be smaller than 1000 kJ/mol nm1. All the covalent bonds
were constrained using the LINCS (Linear Constraint Solver)
algorithm (Hess et al., 1997) to maintain constant bond lengths.
The electrostatic interactions were treated using the Particle Mesh
Ewald (PME) method (Essmann et al., 1995). The cut-off radii for
coulomb and van der Waals interactions were set to 1.2 nm. The
modiﬁed Berendsen (velocity rescaling) thermostat and Parrinello-
–Rahman barostat were applied for 100 ps to keep the system in
stable environmental conditions (310 K, 1 Bar). Finally, after
equilibration of the systems, 10 ns MD were carried out under
the periodic boundary conditions, set at XYZ coordinates to ensure
that the atoms had stayed inside the simulation triclinic box and
the subsequent analyses were then performed.
RMSD, Root Means Square ﬂuctuation (RMSF), radius of
gyration (Rg) and the number of H-bonds formed between the
ligands and the protein, were also evaluated. In addition, to
estimate the binding free energies, the trajectories were used as
input ﬁle for g_mmpbsa package to estimate the binding free
energies (Kumari et al., 2014). The frames were extracted everyFig. 4. Total energy plots of ab-tubulin in complex wit100 ps. Binding free energy for each ligand was calculated from the
difference in free energies for the complexed and un-complexed
reactants, according to the following equation:
DGbind = Gcomplex Gligand Greceptor
3. Results and discussion
3.1. Database screening
A set of 117 thousand compounds were ﬁrst ﬁltered for drug-
like properties, using RO5. In the second level of drug-likeness
screening, ADMET properties were calculated for all hit com-
pounds. The ﬁltered molecules, based on RO5 and ADMET
properties, provided a library of 2204 molecules (Fig. 1).
Then, we used the AutoDock Vina docking program to screen
these molecules. Docking analysis of compounds was carried out to
identify the hits compounds that have lowest binding afﬁnity with
4O2B (Table 1). The reference ligand of 4O2B structure exhibits a
binding afﬁnity value of 9.3 Kcal/mol and its corresponding X-
score was 5.25. Among these compounds, we selected inhibitors
having a binding afﬁnity value higher than 9.3 Kcal/mol and the
X-score value of 5.25. A total of 15 hits showed a binding score and
X-score, much better than the reference ligand. After a careful
analysis based on the non-covalent interactions between theh the top 4 hit compounds during MD simulations.
Fig. 5. RMSF of Ca atoms of ab-tubulin in complex with top 4 hit compounds
during 10 ns MD simulations. A) Alpha subunit; B) Beta subunit and C) Binding site
residues.
Fig. 7. Hydrogen bond formation in hit-protein complexes as a function of time. A)
16814409, B) 17594471, C) 57367244, D) 69899719 and E) Colchicine.
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colchicine (reference ligand), we selected top 4 scoring hits for the
further analyses (Fig. 2).Fig. 6. Time trajectory of radius of gyration of the 3.2. Molecular dynamics simulation of the top 4 hits
MD simulations was performed to further conﬁrm the
reliability of docking results and to obtain a more preciseab-tubulin dimer in complex with top 4 hits.
Fig. 8. 1). PoseView 2D-interaction diagram of the trajectory's last frame of top hit compounds in complex with tubulin (PDB ID: 4O2B). A) 16814409, B) 69899719, C)
17594471 and D) Colchicine. The PoseView interaction analysis is based on hydrogen orientations and protonation states, calculated with Protoss (Bietz et al., 2014). No
interactions were found by the PoseView for compound 57367244. 2). 3D-interaction diagram of the trajectory's last frame of top hit compounds in complex with tubulin
(PDB ID: 4O2B). E) 16814409, F) 69899719, G) 17594471, H) 57367244 and I) Colchicine.
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to explore key residues at the active site of receptor during the
protein-ligand complex simulation. Although, MD simulation is
computationally expensive, but it can take the protein ﬂexibility
and ligand into consideration. The docked structures of the four
selected inhibitors were used as initial structures for MD
simulations. After completion of simulation process, the four
complexes were checked for equilibration of total energy and
RMSD. Analysis of trajectories revealed that all systems in the
simulation were well-equilibrated and remained stable through-
out the simulation of 10 ns (Fig. 3). The total energy plot shows that
the potential energy for all of hits remained more negative as
compared to only protein, which indicates that the complexes
were stable during 10 ns simulation run (Fig. 4). To conﬁrm the
stability of prepared protein in solvent system, the RMSD of
backbone, was calculated after 10 ns simulation. The ﬁnal RMSD
value of tubulin (4O2B) remained below 0.15 nm before and after
the simulation analysis, which indicates that the protein structure
is more rigid in the presence of inhibitors during simulation. All
complexes, except 69899719, had relatively smooth curves; While
for 69899719, the RMSD value suddenly jumped from 0.1 to 0.2 _A at
6.6 ns, which indicated a slight conformational change in 69899719
complex. These results indicate that the dynamic instability of
microtubule is suppressed by Hits. Dynamic instability plays a key
role in determining the organization of microtubules into arrays,
and these arrays vary throughout the cell cycle and assist the cell
division as well.
Also, the RMSF plot of the Ca atom of each residue in the Hits–
4O2B complexes was calculated to reveal the ﬂexibility of tubulin
backbone (Fig. 5). The high RMSF value indicates more ﬂexibility,
whereas the low RMSF value shows limited movements duringsimulation, in relation to its average position over time. The results
showed that the RMSF of the Hits–4O2B complexes is signiﬁcantly
lower than that of only the protein, and some of the residues
constituting the binding pocket of protein, had lower RMSF values
as compared to only tubulin (Fig. 5C). Therefore, the lower RMSF
values of the complexes indicates the lesser extent of conforma-
tional changes and it suppressed the dynamic instability of
microtubules as well.
The Radius of gyration (Rg) measures the distance of a region’s
parts from its center of gravity. It is deﬁned as the mass weighted
root mean square distance of a collection of atoms from their
common center of mass or in other words, how packed a certain
region is. This allows theoretical scientists to check their models
against reality. As it is evident from Fig. 6, the Rg of each complex
remained stable during simulation run. This reveals the stabiliza-
tion and non-signiﬁcant conformational changes in the structure
of all complexes except the tubulin that has a dynamic structure.
A potent inhibitor is thought to form the hydrogen bonding
interactions with protein. Hydrogen bonds play a vital role in
stabilizing the protein-ligand complexes. Higher number of
intermolecular hydrogen-bond interactions leads to greater
stability of protein-ligand complex. In the present investigation,
hydrogen bond analysis was performed to depict the stability of
top 4 hits and 4O2B (Fig. 7). In the case of 17594471, hydrogen bond
interactions reached a maximum of four and two to three of them
remained for most of the time. While, in the case of 69899719, the
number of hydrogen bonding interactions reached up to three for
some times, except other two. In the case of 16814409, the number
of hydrogen bonding interactions reached three and the two of
them remained between 6 and 10 ns. Complex of hit 57367244 and
4O2B showed two hydrogen bonds in the simulation run, in which
Fig. 8. (Continued)
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Whereas, colchicine–4O2B complex exhibited one H-bond
throughout the simulation time period, which indicates that all
of the hits except 57367244 showed stable and strong H-bonds
with 4O2B.
For a better understanding of interactions between hits and the
residues of 4O2B, a plot was drawn using PoseView. As evidentTable 2
VDW, Electrostatic, Polar solvation, SASA and binding free energies of the hit compoun
Hits van der Waal energy Electrostatic energy 
16814409 237.7  1.4 70.7  1.8 
17594471 224.5  1.3 16.8  2.4 
57367244 240.5  1.1 56.9  2.0 
69899719 229.6  2.3 954.7  3.8 
Colchicine 238.9  1.4 60.6  1.0 from Fig. 8, Val181A residue formed a hydrogen bond with a length
of 3.23 Å in Colchicine–4O2B complex. While Leu246A and
Ala248A residues formed hydrogen bonds with lengths of 2.73
and 2.8 Å in 69899719, respectively. Lys350A and Tyr224A residues
formed hydrogen bonds with the lengths of 3.06 and 2.71 Å in
17594471, respectively. Finally, Gln245A and Thr179A residues
formed hydrogen bonds with a length of 3.07 and 2.91 Å inds in complex with tubulin. All values were calculated as kJ/mol.
Polar solvation
energy
SASA energy Binding energy
214.4  2.2 25.5  0.1 119.4  1.5
208.0  2.8 26.1  0.1 59.5  3.1
188.8  2.2 22.5  0.1 131.2  1.6
236.5  6.0 24.7  0.1 972.6  3.8
161.2  1.0 21.9  0.1 116.1  1.9
Table 3
Prediction of some of ADMET properties of hit compounds using admetSAR server.
Green and red entries indicate the favorable and unfavorable effects or properties of the compounds, respectively.
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compounds in the colchicine site of tubulin is comprehensively
shown in Fig. 8.
3.3. Binding free energy and leadlikeness analysis
In order to quantify the binding afﬁnity of hit compounds to
tubulin, the binding free energies of hits were predicted by MM-
PBSA method. As shown in Table 2, the binding free energy of
colchicine (reference ligand) was observed to be 116.1 kJ/mol,
which indicates that the present hit compounds have strong
binding afﬁnity with tubulin. Compound 17594471 interacted
weakly with important residues in the active site and the binding
free energy of this ligand was not signiﬁcant. The binding free
energies of 57367244 and 16814409 were nearly similar to the
reference ligand but it was encouraging to ﬁnd that compound
69899719 had higher binding free energies as compared to the
reference ligand.
Table 2 In total, more than 20 highly predictive qualitative
classiﬁcation models were applied for the calculation of the
physicochemical property of hit compounds. The ADMETproperties of four of the hit compounds are shown in Table 3.
The excellent ADMET properties of these hits make them
promising candidates as anticancer therapeutic agents. Colchicine
(as reference ligand) is a FDA-approved drug to treat gout in adults,
and to treat a genetic condition called Familial Mediterranean
Fever in adults and children above 4 years (Cerquaglia et al., 2005).
4. Conclusion
In the history of cancer treatment, tubulin inhibitors have
proven to be a magniﬁcently effective strategy to eliminate cancer
cells. So, it seems necessary to identify new drugs for improving
these cancer treatment methods. In this study, we used a
combination of ADMET and structure-based screening approaches
to identify new chromene-based inhibitors for the colchicine
binding site of tubulin. At ﬁrst, as the ﬁrst level of ﬁltering, RO5 and
ADMET properties were applied, and then we used docking studies
as second screening approach. After identifying the hit com-
pounds, MD simulations were performed to further validate our
results. MD trajectories analyses such as the RMSD, RMSF, total
H. Aryapour et al. / Computational Biology and Chemistry 71 (2017) 89–97 97energy, Rg and binding free energy proved that our hit compounds
(PubChem CIDs: 16814409, 17594471, 57367244 and 69899719)
can prove to be potent inhibitors of tubulin. These predicted
inhibitors could bind to the colchicine binding site and, lead to the
depolymerization of microtubules. Reducing the growth rate of
microtubules could result in catastrophic events and ﬁnally cause
cell cycle arrest. In the recent years, computational drug discovery
has turned into one of the most promising methods in drug
discovery. This study demonstrated that how effective these
methods are and how efﬁciently they can predict potent inhibitors
for a certain molecular target.
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